QuidelOrtho Corp
For the period ended Dec 28, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
QDEL$11.52-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Fiscal Year Ended | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| OPERATING ACTIVITIES: | |||
| Net loss | $(1,131.8) | $(2,052.0) | $(10.1) |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||
| Depreciation and amortization | 442.0 | 453.4 | 457.2 |
| Goodwill impairment charge | 700.7 | 1,822.6 | — |
| Asset impairment charge | 9.7 | 56.9 | 4.5 |
| Stock-based compensation expense | 45.9 | 42.1 | 51.6 |
| Change in deferred tax assets and liabilities | 6.3 | (99.3) | (11.6) |
| Payment of accreted interest on contingent and deferred consideration | — | — | (9.7) |
| Loss on extinguishment of debt | 5.1 | — | — |
| Asset write off related to restructuring, integration and other charges | 152.2 | — | — |
| Asset write off related to tax assessment refund | — | 20.0 | — |
| Other non-cash, net | 0.9 | (2.0) | (6.8) |
| Changes in assets and liabilities: | |||
| Accounts receivable | (117.5) | 5.4 | 160.0 |
| Inventories | (148.3) | (134.1) | (211.6) |
| Prepaid expenses and other current and non-current assets | (34.6) | (9.5) | (26.9) |
| Accounts payable | 40.0 | (23.4) | 3.0 |
| Accrued payroll and related expenses | 0.9 | 35.0 | (53.9) |
| Income taxes payable | 41.7 | (9.5) | (59.6) |
| Other current and non-current liabilities | 92.0 | (22.6) | (5.9) |
| Net cash provided by operating activities | 105.2 | 83.0 | 280.2 |
| INVESTING ACTIVITIES | |||
| Acquisitions of property, plant, equipment, investments and intangibles | (188.2) | (195.1) | (209.3) |
| Proceeds from held for sale asset, net of costs to sell | — | 9.3 | — |
| Proceeds from government assistance allocated to fixed assets | 6.5 | — | 13.5 |
| Purchases of marketable securities | — | (7.2) | (60.1) |
| Proceeds from sale of marketable securities | — | 63.1 | 78.3 |
| Loan to LEX Diagnostics | (11.0) | (20.0) | (10.0) |
| Net cash used for investing activities | (192.7) | (149.9) | (187.6) |
| FINANCING ACTIVITIES | |||
| Proceeds from issuance of common stock | 6.1 | 5.0 | 11.6 |
| Short-term borrowings, net | 3.0 | (1.6) | 1.6 |
| Revolving credit facility, net | (118.0) | 198.0 | — |
| Proceeds from long-term borrowings, net of discount and debt issuance costs | 2,559.3 | — | — |
| Payments on long-term borrowings | (2,289.2) | (143.0) | (228.0) |
| Payments of tax withholdings related to vesting of stock-based awards | (5.4) | (9.6) | (13.5) |
| Repurchases of common stock | — | — | (7.2) |
| Principal payments of deferred consideration | — | — | (30.3) |
| Net cash provided by (used for) financing activities | 155.8 | 48.8 | (265.8) |
| Effect of exchange rates on cash | 3.0 | (2.9) | (1.2) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 71.3 | (21.0) | (174.4) |
| Cash, cash equivalents and restricted cash at beginning of period | 98.5 | 119.5 | 293.9 |
| Cash, cash equivalents and restricted cash at end of period | $169.8 | $98.5 | $119.5 |
| Fiscal Year Ended | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | |||
| Cash paid during the period for interest | $172.4 | $177.5 | $150.0 |
| Cash (received) paid for income taxes during the period | $(25.4) | $41.6 | $86.6 |
| Purchase of property, equipment and intangibles by incurring current liabilities | $13.3 | $25.9 | $40.6 |
| Transfer of instrument inventories to property, plant and equipment | $167.3 | $148.9 | $154.6 |
| Reduction of other current liabilities upon issuance of restricted share units | $0.8 | $0.3 | $1.9 |
| Initial recognition of finance lease right-of-use asset and liability | $— | $12.5 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.